TURNING POINT THERAPEUTICS I (TPTX)

Company Profile

Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. The company is headquartered in San Diego, California and currently employs 248 full-time employees. The company went IPO on 2019-04-17. The firm is engaged in designing and developing therapies that target genetic drivers of cancer to improve the lives of patients. The company develops a macrocycle platform from which it designs its pipeline of small, compact tyrosine kinase inhibitors (TKIs). The TKIs generated from its drug discovery platform address unmet needs in TKI naive and resistance settings. The Company’s drug candidate, repotrectinib (TPX-0005), is in Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with NTRK+ or ALK+ advanced solid tumors. Its multi-cohort Phase II registrational portion of TRIDENT-1 is ongoing at sites in North America, Europe and the Asia-Pacific regions. The Company’s pipeline includes multi-targeted kinase inhibitors: TPX-0046 (a novel RET inhibitor), Elzovantinib (TPX-0022) (a novel MET/CSF1R/SRC inhibitor) and TPX-0131.

Company Info

TURNING POINT THERAPEUTICS I

10628 Science Center Drive, Suite 200

San Diego CALIFORNIA 92121

P: 18589265251.0

CEO: Athena Countouriotis

Employees: 248

Website: https://www.tptherapeutics.com/